Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Recurrent Breast Cancer
Interventions: DRUG: Nab-paclitaxel|DRUG: IG-001
Sponsor: Sorrento Therapeutics, Inc.